Denosumab

Endocrinology

Endocrinology · RANKL monoclonal antibody

Denosumab

Dose

60 mg SC every 6 months (osteoporosis); 120 mg SC monthly in skeletal metastases.

Use

Osteoporosis when bisphosphonates unsuitable — including CKD.

Monitoring

Calcium before each dose, dental health; never stop abruptly (rebound vertebral fractures).

Side effects

  • Hypocalcaemia
  • Cellulitis
  • Osteonecrosis of jaw
  • Rebound fracture on discontinuation

Related in WardRound

Always confirm dose against your local formulary / BNF before prescribing.

WardRound

WardRound

Clinical Decisions in Seconds